To evaluate the adequacy of maternal pyridoxine supple mentation during pregnancy for both maternal and neonatal status at birth, vitamin B6 status, assessed by plasma pyridoxal phosphate (PLP), pyridoxal (PL) and total aldehyde vitamer (PLP+PL) concentrations, and the growth of neonates, including weight, length, head and chest circumferences, were examined for 209 neonates whose mothers were supplemented with 0, 1, 2 or 3mg pyridoxine• HCl (PN• HCl)/d during pregnancy. Maternal PN• HCl supplementations were positively correlat ed to both maternal (r=0.62) and cord (r=0.78) plasma PLP concen trations (p<0.0001). Mothers supplemented with 2 or 3mg/d PN• HCl had significantly higher plasma concentrations of PLP and total B6 aldehyde vitamer in maternal and cord blood compared with those receiving 0 or 1mg PN• HCl/d. A growth benefit for neonates whose mothers had maternal and cord plasma PLP concentrations _??_40nM was revealed by the maternal supplementation of 2mg PN• HCl/d during pregnancy. Thus, in healthy pregnant women, according to our study, a daily supplement of 2mg PN• HCl provides the adequacy of maternal and neonatal vitamin B6 status and the satisfactory growth of neonates at birth. Key Words pyridoxine supplement, B6 vitamers, nutritional status, pregnancy, neonate Maternal vitamin B6 supplementation has been studied extensively, yet information concerning adequacy for the vitamin during pregnancy is equivocal. The current U.S.RDA was based on the additional vitamin B6 needed for the increased protein allowance for pregnancy (1). No allowance was made to compensate for either increased fetal and maternal metabolic needs for vitamin B6 (2) or hormonal induction of vitamin B6 dependent enzyme (3-6). Studies show that pregnant women have significantly lower levels of both vitamin B6 and pyridoxal-5-phosphate (PLP) in plasma and decreased activities of erythrocyte *
Maternal vitamin B6 supplementation has been studied extensively, yet information concerning adequacy for the vitamin during pregnancy is equivocal. The current U.S.RDA was based on the additional vitamin B6 needed for the increased protein allowance for pregnancy (1) . No allowance was made to compensate for either increased fetal and maternal metabolic needs for vitamin B6 (2) or hormonal induction of vitamin B6 dependent enzyme (3) (4) (5) (6) . Studies show that pregnant women have significantly lower levels of both vitamin B6 and pyridoxal-5-phosphate (PLP) in plasma and decreased activities of erythrocyte alanine aminotransferase (ALAT), as well as decreased PLP saturation of the enzyme compared to values for nonpregnant women (7) (8) (9) . PLP levels in maternal plasma in late pregnancy and in cord plasma were particularly low in women who did not take vitamin B6 supplements during pregnancy.
Several studies show that pregnant women require at least 4mg/d of vitamin B6. Levels up to 10mg/d may be needed by some women during pregnancy to normalize both maternal and fetal biochemical indices of vitamin B6 status (2 , 7, 10-13). The essentiality of vitamin B6 for normal development of the central ner vous system of rat pups is well documented (14-16). In human studies, a multiple-regression analysis of nutrient and non-nutrient variables showed that the vitamin B6 status of the mother was the strongest factor affecting neurobehavioral development of infants and maternal-infant interactions (17) . Additionally, Heiskanen et al (18) suggested that gestationally accumulated stores were important for the maintenance of adequate vitamin B6 status of infants during the early months of infancy.
The importance of vitamin B6 sufficiency for the pregnant women is evident. Hence, this study was designed to evaluate the adequacy of maternal vitamin B6 supplementation in relation to the vitamin B6 status of both mother and neonate, and the general well-being of neonates at birth. Both plasma PLP and PL mea surements were suggested requirements for an accurate assessment of vitamin B6 nutritional status and a proper understanding of vitamin B6 physiology, especially during pregnancy (19) (20) (21) . Maternal vitamin B6 supplementation and nutritional status data, in conjunction with that for vitamin intake, plasma PLP and PL concentrations and growth of neonates were used to determine both the effect of maternal vitamin B6 supplementation on the vitamin B6 status of mother and neonate and on the growth of the neonate. Length, weight, and head and chest circumference measurements of the neonates were obtained at birth. Apgar scores of neonates at 1 and 5min after birth were also collected. All measurements were made by one individual, a trained pediatric nurse. An electronic balance (New-series, New-20K, Japan) was used to obtain neonatal weights. Lengths were measured with a portable tape board equipped with a head and foot board. Pediatric tapes were used for head and chest circumference measurements.
MATERIALS AND METHODS
A computer program from the Statistical Analysis System (SAS) (24) was used. Vitamin B6 intakes of mothers The mean dietary vitamin B6 intake of the pregnant women was not significantly different among the groups, and approximately 1.0mg/d. Among these, 0.75mg/d of vitamin B6 was ingested from rice which was the main dish of these women. The differences of total vitamin B6 intake among the groups were attributed to the 
Growth of neonates
The growth measurements at birth including weight, length, and head and chest circumferences were not significantly different among neonates whose mothers were supplemented with different levels of PN• HCl/d. However, the birth weights of neonates born with PLP concentrations of_??_40nM in the cord plasma were significantly greater than those with <40nM PLP at birth (Table 6 ). Length, head and chest circumferences of neonates with plasma PLP of _??_40nM were greater than those with <40nM PLP, although the difference was not statistically significant. Mothers supplemented with 2 or 3mg/d PN• HCl had significantly higher plasma concentrations of PLP and total B6 aldehyde vitamer in the maternal and cord blood compared with those supplemented with 0 or 1mg PN• HCl/d. If plasma PLP of <30nM is used as a cut-off point for vitamin B6 inadequacy (39) , the results of the present study (Tables 2 and 3 ) suggest that 2mg PN• HCl/d of maternal supplement resulted in relatively optimal levels of vitamin B6 nutritional status in both the mother and neonate.
Growth measurements for neonates with plasma PLP concentrations of _??_40nM were greater than those with <40nM PLP (Table 6 ). Low vitamin B6 status associated with failure to gain weight (40, 41) and reduced gain in length (41, 42) has been found in human infants. The Apgar scores at 1 and 5min were also correlated with PLP concentrations in the cord plasma. The results of this study showed a growth benefit for neonates when the plasma PLP concentration in the placental cord was _??_40nM, which was reflected by the maternal supplement of 2mg PN• HCl/d during pregnancy. This study was supported by the Department of Health, Republic of China (Grants DOH-81-TD-101). Appreciation is expressed to the physicians and clinical staff from the study hospitals for their invaluable help in the recruitment of subjects and in sample collection. 
